TD Cowen analyst Steve Scala maintained a Buy rating on AstraZeneca (AZN – Research Report) today. The company’s shares closed yesterday at ...

In a report released today, James Gordon from J.P. Morgan maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target ...

AstraZeneca PLC AZN shares rose 1.11% to £107.12 Monday, on what proved to be an all-around great trading session for the ...

A PNG side at a trial match in Sydney in 2013 Papua New Guinea (PNG) will join Australia's national rugby league competition, after signing a deal that obligates them to shun security ties with China.

In return, PNG has entered an agreement designed to stop China gaining a security foothold in the Pacific nation. PNG's capital Port Moresby will host home games for the new team, whose name and ...

In the case of PNG, it was the federal government’s backing that proved crucial – Australian taxpayers will provide $600 million over the next 10 years to help establish the team, with $120 ...

Papua New Guinea (PNG) will join Australia's national rugby league competition, after signing a deal that obligates them to shun security ties with China. The Pacific nation has produced many ...

Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry. Both have generally produced strong financial results in 2024, but one wouldn ...

LONDON, Dec 24 (Reuters) - AstraZeneca (AZN.L), opens new tab has voluntarily withdrawn its marketing authorisation application with the EU's medicines regulator for its experimental precision ...

U.K.-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) is making news, but not in a good way. Its operations in China were recently rocked when Leon Wang, the company's president in the country ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for legal issues in China. One of these stocks has a stronger investment ...

AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc (NYSE:MRK), on Wednesday, announced long-term results from the OlympiA Phase 3 trial. The trial showed Lynparza (olaparib) demonstrated sustained ...